Drugs / GM103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06265025 | Feb 2024 → May 2025 overdue | breast cancer, cervical cancer, colorectal cancer, head and neck cancer +2 | GeneMedicine Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GM103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06265025 ↗ |